ArticleCancers2022

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial.

Deyue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.